Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sofosbuvir + daclatasvir for chronic hepatitis C in Egyptian adults and children
ACTRN12617000263392Phase 4Completed
- Sponsor
- Green CRC
- Start
- Jun 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of daclatasvir in hepatitis C virus infection (2 arms), sponsored by Green CRC. Primary endpoint: SVR12 non-inferiority. Started Jun 2016; status: completed.
02
Drugs
daclatasvir
03
Conditions
hepatitis C virus infection
Beyond the preview
Go deeper on ACTRN12617000263392.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12617000263392.